SGHT vs. INO, TLSI, GUTS, UTMD, ANGO, RCEL, CERS, TCMD, LUNG, and PROF
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include Inovio Pharmaceuticals (INO), TriSalus Life Sciences (TLSI), Fractyl Health (GUTS), Utah Medical Products (UTMD), AngioDynamics (ANGO), AVITA Medical (RCEL), Cerus (CERS), Tactile Systems Technology (TCMD), Pulmonx (LUNG), and Profound Medical (PROF). These companies are all part of the "surgical & medical instruments" industry.
Sight Sciences (NASDAQ:SGHT) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.
Inovio Pharmaceuticals received 702 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 71.49% of users gave Inovio Pharmaceuticals an outperform vote while only 31.91% of users gave Sight Sciences an outperform vote.
In the previous week, Inovio Pharmaceuticals had 28 more articles in the media than Sight Sciences. MarketBeat recorded 29 mentions for Inovio Pharmaceuticals and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.75 beat Inovio Pharmaceuticals' score of 0.27 indicating that Sight Sciences is being referred to more favorably in the media.
Sight Sciences presently has a consensus target price of $4.70, indicating a potential downside of 11.99%. Inovio Pharmaceuticals has a consensus target price of $70.67, indicating a potential upside of 488.89%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Sight Sciences.
Sight Sciences has a beta of 2.73, meaning that its stock price is 173% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 27.1% of Sight Sciences shares are owned by insiders. Comparatively, 2.5% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Sight Sciences has a net margin of -67.18% compared to Inovio Pharmaceuticals' net margin of -16,238.91%. Sight Sciences' return on equity of -44.45% beat Inovio Pharmaceuticals' return on equity.
Sight Sciences has higher revenue and earnings than Inovio Pharmaceuticals.
Summary
Sight Sciences beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
